BR112021016996A8 - Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana - Google Patents

Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana

Info

Publication number
BR112021016996A8
BR112021016996A8 BR112021016996A BR112021016996A BR112021016996A8 BR 112021016996 A8 BR112021016996 A8 BR 112021016996A8 BR 112021016996 A BR112021016996 A BR 112021016996A BR 112021016996 A BR112021016996 A BR 112021016996A BR 112021016996 A8 BR112021016996 A8 BR 112021016996A8
Authority
BR
Brazil
Prior art keywords
composition
antibacterial
prevent
present
antibacterial activity
Prior art date
Application number
BR112021016996A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112021016996A2 (https=
Inventor
Min Park Yeong
Kim Yangmee
Duk Jung In
Lee Seung-Hyun
Original Assignee
Dandi Bioscience Inc
Hlb Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200023629A external-priority patent/KR102368983B1/ko
Application filed by Dandi Bioscience Inc, Hlb Science Inc filed Critical Dandi Bioscience Inc
Publication of BR112021016996A2 publication Critical patent/BR112021016996A2/pt
Publication of BR112021016996A8 publication Critical patent/BR112021016996A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
BR112021016996A 2019-02-28 2020-02-27 Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana BR112021016996A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190023534 2019-02-28
KR1020200023629A KR102368983B1 (ko) 2019-02-28 2020-02-26 항균활성을 갖는 폴리펩타이드, 이를 포함하는 패혈증 예방 또는 치료용 조성물, 및 항균용 조성물
PCT/KR2020/002826 WO2020175936A1 (ko) 2019-02-28 2020-02-27 항균활성을 갖는 폴리펩타이드, 이를 포함하는 패혈증 예방 또는 치료용 조성물, 및 항균용 조성물

Publications (2)

Publication Number Publication Date
BR112021016996A2 BR112021016996A2 (https=) 2021-11-30
BR112021016996A8 true BR112021016996A8 (pt) 2022-11-22

Family

ID=72239598

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016996A BR112021016996A8 (pt) 2019-02-28 2020-02-27 Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana

Country Status (5)

Country Link
US (1) US12371453B2 (https=)
JP (1) JP7219512B2 (https=)
BR (1) BR112021016996A8 (https=)
CA (1) CA3168643A1 (https=)
WO (1) WO2020175936A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230287048A1 (en) * 2020-03-20 2023-09-14 HLB Science Inc. Composition and kit for removing lipopolysaccharide
CN115960171B (zh) * 2022-10-12 2023-08-29 东北农业大学 高稳定性Trp-pocket跨链交互型β-发卡抗菌肽及制备方法和应用
CN120865346A (zh) * 2024-04-26 2025-10-31 深圳碳云智肽药物科技有限公司 小分子抗菌多肽、制备方法及其应用
CN118406113B (zh) * 2024-05-10 2025-04-22 东北农业大学 具有lps结合能力的靶向革兰氏阴性菌的抗菌肽及其制备方法和应用
CN118955633B (zh) * 2024-07-19 2025-05-09 东北农业大学 富含D-Arg的抗酶解十四肽2rrr及其制备方法和应用
CN118667035A (zh) * 2024-07-24 2024-09-20 兰州大学 一类抗菌基序修饰的广谱低耐药抗菌肽及其应用
CN119591691B (zh) * 2025-01-10 2025-10-21 福建农林大学 基于大黄鱼cxcl8蛋白的抗菌肽及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608277B2 (en) * 2004-12-01 2009-10-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
ES2716474T3 (es) 2007-10-26 2019-06-12 Avivagen Inc Composiciones y métodos para mejorar la respuesta inmunitaria
DK2344178T3 (en) * 2008-10-05 2015-02-16 Univ Siena Peptide sequences, their branched form and their use for antimicrobial applications
TWI685505B (zh) * 2011-05-20 2020-02-21 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
MX357938B (es) 2011-06-19 2018-07-31 Univ New York Metodos para tratar y prevenir infecciones por staphylococcus aureus y afecciones asociadas.
ES2890555T3 (es) 2014-01-29 2022-01-20 Enzymatica Ab Tripsina de bacalao para uso en el tratamiento de infecciones microbianas en un sujeto con inmunodeficiencia
JP6338899B2 (ja) * 2014-03-18 2018-06-06 国立研究開発法人産業技術総合研究所 両生類ネッタイツメガエル皮膚由来機能性ペプチド
KR101477795B1 (ko) 2014-04-23 2015-01-02 건국대학교 산학협력단 Ａｄｋ 단백질을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물
KR101785050B1 (ko) 2014-12-10 2017-10-13 건국대학교 글로컬산학협력단 Ａｄｋ 단백질 및 항생제를 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물
EP3292765A4 (en) 2015-04-03 2019-03-13 Konkuk University Glocal Industry-Academic Collaboration Foundation ANTIBACTERIAL COMPOSITION FOR THE CONTROL OF CARBAPENEMA-RESISTANT GRAM NEGATIVE BACTERIA COMPRISING AN ADK PROTEIN AS ACTIVE INGREDIENT
EP3351553A4 (en) * 2015-09-17 2019-06-19 Seoul National University R & DB Foundation BROKEN OR FOLDED HELIXFUL PEPTIDE OR PEPTIDE ANALOG WITH ANTIMICROBIAL ACTIVITY AGAINST GRAM NEGATIVE BACTERIA AND USE THEREOF
KR101792239B1 (ko) 2016-11-01 2017-10-31 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산 및 항생제를 유효성분으로 포함하는 항균 조성물
AU2018285437B2 (en) 2017-06-16 2020-10-15 Borealis Ag A polymer composition for photovoltaic applications
EP3641746B1 (en) 2017-06-19 2024-11-20 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
KR102011676B1 (ko) 2017-08-29 2019-08-19 (주) 한성스틸 벽난로
US20230287048A1 (en) * 2020-03-20 2023-09-14 HLB Science Inc. Composition and kit for removing lipopolysaccharide
KR102709142B1 (ko) * 2020-08-27 2024-09-26 에이치엘비사이언스 주식회사 알츠하이머 치매 예방 또는 치료용 펩타이드 조성물

Also Published As

Publication number Publication date
US12371453B2 (en) 2025-07-29
JP7219512B2 (ja) 2023-02-08
JP2022521543A (ja) 2022-04-08
CA3168643A1 (en) 2020-09-03
BR112021016996A2 (https=) 2021-11-30
US20220144892A1 (en) 2022-05-12
WO2020175936A1 (ko) 2020-09-03

Similar Documents

Publication Publication Date Title
BR112021016996A8 (pt) Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana
CR20160269A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento del cancer y enfermedades comunes
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
DOP2017000186A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
ECSP12012017A (es) DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2019011061A (es) Compuestos útiles en el tratamiento o prevención de un trastorno mediado por la proteína arginina metil-transferasa 5 (prmt5).
CR20120631A (es) Agentes inductores de apoptosis para el tratamiento del càncer y de enfermedades inmunes y autoinmunes
UY33047A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
BR112015022483A2 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
BR112017010602A2 (pt) análogos de ureia ligados em ponte substituídos como moduladores de sirtuína
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
BR112021018918A2 (pt) Compostos e composições como moduladores de sinalização de tlr
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
MX394323B (es) Uso de una composición antibacteriana para tratar infecciones por estafilococos.
BR112021011293A2 (pt) Composição farmacêutica para prevenção ou tratamento de câncer compreendendo lactobacillus sakei wikim30 como ingrediente ativo
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
MX2023008501A (es) Composiciones y metodos para remodelar el cuerpo y procedimientos quirurgicos.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: HLB SCIENCE INC. (KR)

B25G Requested change of headquarter approved

Owner name: HLB SCIENCE INC. (KR)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]